文献速递前列腺癌

基因组前列腺评分识别前列腺癌生物学低危疾病:主动监测、手术或放疗患者分析

Genomic Prostate Score for Identifying Biologically Low-risk Disease in Patients with Prostate Cancer Undergoing Active Surveillance, Surgery, or Radiotherapy.
PubMed 文献 · Eur Urol Oncol · 2026-06-25

该回顾性研究评估17基因基因组前列腺评分(GPS)在409例临床局限性和局部晚期前列腺癌患者中的降阶梯管理潜力,患者接受主动监测(AS)、根治性前列腺切除术(RP)或放疗(RT),中位随访≥6年。低GPS评分者占58%,其中与NCCN风险分组不一致的「不一致低危」表型在各治疗组中普遍存在,6年无事件生存率与「一致低危」患者相近。

要点

  • 低GPS评分者占研究人群58%,其中与NCCN分组不一致的低危表型常见。
  • 不一致低危患者6年无事件生存率:AS 88%、RP和RT 100%、局部晚期95%。
  • 结果为未来利用基因组分类器进行靶向降阶梯管理的试验提供可行性依据。

核心结论

  • 在临床风险较高但GPS评分低的患者中,6年结局良好,支持未来开展利用基因组分类器进行靶向管理降阶梯的试验。

研究设计与样本

  • 回顾性评估17基因基因组前列腺评分(GPS),纳入409例临床局限性和局部晚期前列腺癌患者,中位随访≥6年,管理方式为主动监测(AS)、根治性前列腺切除术(RP)或放疗(RT)。

主要发现

  • 低GPS评分者占研究人群58%,按与NCCN风险分组的一致性分为「一致低危」和「不一致低危」组。
  • 不一致低危表型占NCCN≥2 AS患者的46%、NCCN≥3 RP患者的57%、NCCN≥4 RT患者的36%、NCCN5局部晚期患者的48%。
  • 不一致低危患者6年无事件生存率:AS 88%、RP和RT 100%、局部晚期组95%。
  • 所有「一致低危」(低GPS且NCCN较低风险)患者6年无治疗生存率为100%。

关键数值与推荐

  • 低GPS评分定义为占研究人群58%的低评分患者。
  • 不一致低危定义为NCCN≥2但GPS评分低。

临床怎么用

  • 对于临床风险较高但GPS评分低的患者,可考虑在试验框架下评估管理降阶梯的可行性。

局限性

  • 为回顾性研究,降阶梯潜力需前瞻性试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Validated genomic classifiers are recommended for use when this may change the management of patients with prostate cancer (PCa). However, their potential for management de-escalation is unclear. Here, we retrospectively evaluated the 17-gene Genomic Prostate Score (GPS) in patients with clinically localised and locally advanced PCa (n = 409; median follow-up ≥6 yr) managed with active surveillance (AS), radical prostatectomy (RP), or radiotherapy (RT). To evaluate de-escalation potential against metastasis and European Association of Urology (EAU) high-risk biochemical recurrence (BCR), patients with low GPS scores (58% of the study population) were stratified into "concordant" and "discordant" low-risk groups based on agreement with standard National Comprehensive Cancer Network (NCCN) risk categories. The "discordant low-risk" phenotype (NCCN ≥2 but low GPS) proved highly prevalent, comprising 46% of NCCN≥2 AS, 57% of NCCN≥3 RP, 36% of NCCN≥4 RT, and 48% of NCCN5 locally advanced patients. Six-yr event-free survival estimates in these patients were 88% in AS, 100% in RP and RT, and 95% in the locally advanced groups, similar to the 100% 6-yr treatment-free survival seen in all "concordant low-risk" (low GPS and lower-risk NCCN) patients. Overall, identifying a prevalent group with favourable 6-yr outcomes despite high clinical risk supports the feasibility of future trials using genomic classifiers for targeted management de-escalation.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Sushentsev N, Colling R, Teague R, et al. Genomic Prostate Score for Identifying Biologically Low-risk Disease in Patients with Prostate Cancer Undergoing Active Surveillance, Surgery, or Radiotherapy. Eur Urol Oncol. 2026. PMID: 42350192. doi:10.1016/j.euo.2026.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。